Chair, Department of Chemical Physiology, The Scripps Research Institute; Co-director, Center for Physiological Proteomics, The Scripps Research Institute
Managing Director, D.E. Shaw and Co., L.P.
VP of Research & Policy, Ewing Marion Kauffman Foundation
Professor, Michigan State University
Prescience International has asked three members of MedImmune Ventures to give an overview of their key areas of interest, background on their portfolio, and best practices in venture capital investing. MedImmune Ventures has been fostering innovation and entrepreneurship by investing in emerging healthcare companies since 2002. MedImmune Ventures is a wholly-owned venture capital fund within the AstraZeneca Group, and invests in private companies that develop small and large molecules, vaccines, pharmaceutical technologies and platforms. They also fund investments in medical device, diagnostics, imaging and healthcare IT companies that relate to the discovery, development and commercialization of pharmaceutical products. More information and online registration is here.